Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer

Journal of Experimental & Clinical Cancer Research

Feng Li¹  Yu-Cong Li¹  Xiao-Ming Du¹  Yi-Xiao Li¹  Guo-Xing Wan¹  Wen-Qin Li¹  Yu-Wen Cao¹ 

[1]Department of Pathology and Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832000, Xinjiang, China

关键词: Prognosis;    Breast cancer;    Snail;    N1IC;    SIRT1;   

Others  :  1145499
DOI  :  10.1186/s13046-014-0097-2

 received in 2014-08-20, accepted in 2014-11-07,  发布年份 2014

【 摘 要 】

Background

SIRT1 expression and Notch1 signaling have been implicated in tumorigenesis in many cancers, but their association with survival in breast cancer has not been determined. The purpose of this study was to assess the possible prognostic value of SIRT1, N1IC, and Snail expression in breast cancer patients.

Methods

Immunohistochemistry was performed to examine the expression of SIRT1, N1IC, and Snail, and the combined expression of SIRT1 and N1IC, using tissue microarrays containing breast cancer tissue and matched adjacent normal breast tissue from 150 breast cancer patients. Survival analysis was carried out using the Kaplan-Meier method. Univariate and multivariate analysis were used to evaluate the prognostic value of SIRT1, N1IC, Snail and combined SIRT1/N1IC expression, in addition to other clinicopathological factors, including grade, lymph node status, disease stage, and estrogen, progesterone, and human epidermal growth factor receptor 2 receptor status in breast carcinoma patients.

Results

SIRT1, N1IC, and Snail were all found to be highly expressed and an inverse correlation between SIRT1 and N1IC in breast cancer tissue. The three markers significantly correlated with lymph node status. Patients with low SIRT1 expression exhibited shorter overall survival (OS) and disease-free survival (DFS), and patients with combined low expression of SIRT1 and high expression of N1IC had the worse OS and DFS. Univariate and multivariate survival analysis revealed that low expression of SIRT1 and SIRT1-low/N1IC-high expression were independent prognostic factors for poor survival.

Conclusions

These results suggest that low expression of SIRT1 or the combined low expression of SIRT1 and high expression of N1IC could be used as indicators of poor prognosis, and may represent novel therapeutic targets in breast cancer.

【 授权许可】

   
2014 Cao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu T, Guarente L, Kashiwagi A, Koya D: SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 2007, 282(1):151-158.
• [2]Ao N, Liu Y, Feng H, Bian X, Li Z, Gu B, Zhao X, Liu Y: Ubiquitin-specific peptidase USP22 negatively regulates the STAT signaling pathway by deubiquitinating SIRT1. Cell Physiol Biochem 2014, 33(6):1863-1875.
• [3]Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, Moon WS, Felsher DW, Sylvester KG: SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One 2012, 7:e45119.
• [4]Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA: hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107(2):149-159.
• [5]Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107(2):137-148.
• [6]Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123(3):437-448.
• [7]Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303(5666):2011-2015.
• [8]Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY: Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011, 42(2):204-213.
• [9]Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, Kong Y, Lv N, Jia W, Zhang Y, Xie X: Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol 2012, 29(5):3240-3249.
• [10]Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T, Inomata M, Miwa T, Matsui S, Usui I, Urakaze M, Matsuya Y, Ogawa H, Sakurai H, Saiki I, Tobe K: SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep 2012, 27(6):1726-1732.
• [11]Yuan J, Minter-Dykhouse K, Lou ZK: A c-Myc¿SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 2009, 185(2):203-211.
• [12]Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L: SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep 2013, 3(4):1175-1186.
• [13]Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, Zhu WG: Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of P21Waf1/Cip1. Mol Cell Biol 2006, 26(7):2782-2790.
• [14]Xie M, Liu M, He C-S: SIRT1 Regulates endothelial notch signaling in lung cancer. Plos One 2012, 7(9):1-11.
• [15]Wang XQ, Zhang W, Lui EL, Zhu Y, Lu P, Yu X, Sun J, Yang S, Poon RT, Fan ST: Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. Int J Cancer 2012, 131(3):163-172.
• [16]Guo Z, Jin X, Jia H: Inhibition of ADAM-17 more effectively down-regulates the Notch pathway than that of ?-secretase in renal carcinoma. J Exp Clin Cancer Res 2013, 32(1):26-34. BioMed Central Full Text
• [17]Huang J, Song H, Liu B, Yu B, Wang R, Chen L: Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma. J Exp Clin Cancer Res 2013, 32(1):84-92. BioMed Central Full Text
• [18]Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, Miele L: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002, 8(9):979-986.
• [19]Wang J, Fu L, Gu F, Ma Y: Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep 2011, 26(5):1295-1303.
• [20]Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, Er?ahin Ç, Rajan P: Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol 2012, 20(2):139-145.
• [21]Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005, 65(18):8530-8537.
• [22]Yao K, Rizzo P, Rajan P, Albain K, Rychlik K, Shah S, Miele L: Notch-1 and notch-4 receptors as prognostic markers in breast cancer. Int J Surg Pathol 2011, 19(5):607-613.
• [23]Mantel CR, Wang RH, Deng C, Broxmeyer HE: Sirt1, notch and stem cell ¿age asymmetry¿. Cell Cycle 2008, 7(18):2821-2825.
• [24]Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S, Sato M, Horio Y: Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci U S A 2008, 105(40):15599-15604.
• [25]Sciacca S, Pilato M, Mazzoccoli G, Pazienza V, Vinciguerra M: Anti-correlation between longevity gene SirT1 and Notch signaling in ascending aorta biopsies from patients with bicuspid aortic valve disease. Heart Vessels 2013, 28(2):268-275.
• [26]Guarani V, Deflorian G, Franco CA, Kruger M, Krüger M, Phng LK, Bentley K, Toussaint L, Dequiedt F, Mostoslavsky R, Schmidt MH, Zimmermann B, Brandes RP, Mione M, Westphal CH, Braun T, Zeiher AM, Gerhardt H, Dimmeler S, Potente M: Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 2011, 473(7346):234-238.
• [27]Kitajewski J: Fine-tuning endothelial Notch: SIRT-ainly an unexpected mechanism. Dev Cell 2011, 20(5):577-578.
• [28]Ban J, Aryee DN, Fourtouna A, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Schwentner R, Picci P, Flanagan AM, Berg V, Strauss SJ, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H: Suppression of deacetylase SIRT1 mediates tumor suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. Cancer Res 2014, 74(22):1736-1746.
• [29]Jethwa P, Naqvi M, Hardy RG, Hotchin NA, Roberts S, Spychal R, Tselepis C: Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol 2008, 14(7):1044-1052.
• [30]Jung W, Hong KD, Jung WY, Lee E, Shin BK, Kim HK, Kim A, Kim BH: SIRT1 Expression is associated with good prognosis in colorectal cancer. Korean J Pathol 2013, 47(4):332-339.
• [31]Kuo SJ, Lin HY, Chien SY, Chen DR: SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein. Oncol Rep 2013, 30(1):125-130.
• [32]Moore RL, Faller DV: SIRT1 represses estrogen-signaling, ligand-independent ER?-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol 2013, 216(3):273-285.
• [33]Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS, Jang KY: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009, 15(13):4453-4459.
• [34]Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009, 41(4):366-371.
• [35]Choi HN, Bae JS, Jamiyandorj U, Noh SJ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep 2011, 26(2):503-510.
• [36]Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, Kang MJ, Lee DG, Kim HS, Shim H, Moon WS: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008, 32(10):1523-1531.
• [37]Ben-lin HUA, Xin-ge FU, Feng LI: The compare of Notch1 and JAG1expression in breast cancer and adjacent normal breast tissues. Chin J Clin Exp Pathol 2009, 25(2):127-131. (in Chinese)
• [38]Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S: Activation of NF-?B by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res 2013, 32(1):62-70. BioMed Central Full Text
• [39]Kim HS, Jung G: Notch1 increases Snail expression under high reactive oxygen species conditions in hepatocellular carcinoma cells. Free Radic Res 2014, 48(7):806-813.
• [40]Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD: Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res 2011, 9(12):1644-1657.
• [41]Dubois-Marshall S, Thomas JS, Faratian D, Harrison DJ, Katz E: Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer. Clin Exp Metastasis 2011, 28(8):811-818.
• [42]Sierra RA, Thevenot P, Raber PL, Cui Y, Parsons C, Ochoa AC, Trillo-Tinoco J, Valle LD, Rodriguez PC: Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer. Cancer Immunol Res 2014, 2(8):800-811.
• [43]Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A, Christensen JG: Synergistic effect of the ?-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med 2013, 2(3):233-242.